Lynk Pharmaceuticals Reveals Promising Phase II Results for LNK01004 in Atopic Dermatitis Treatment Lynk Pharmaceuticals has announced promising results from Phase II clinical trials of LNK01004, a treatment for atopic dermatitis, showcasing both efficacy and safety.

Lynk Pharmaceuticals Reveals Promising Phase II Results for LNK01004 in Atopic Dermatitis Treatment #China #Hangzhou #Atopic_Dermatitis #Lynk_Pharmaceuticals #LNK01004